Clinical trial
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
NCT01456182 is registered in ClinicalTrials.gov with Afexa Life Sciences Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
- Lead sponsor
- Afexa Life Sciences Inc
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- December 31, 2011
- Completion date
- May 31, 2013
- Enrollment
- 0 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.